Amarin Moves Beyond Bridge Financing With $70 Million Private Placement
This article was originally published in The Pink Sheet Daily
Executive Summary
Existing and new investors are drawn by the potential of a compound that would compete with statins in the dyslipidemia market.
You may also be interested in...
Amarin Accelerates Timeline For NDA Filing Of AMR101
Positive results from a Phase III trial of Amarin Corporation's triglyceride-lowering drug AMR101 will allow the company to submit its NDA to FDA in 2011, a year ahead of schedule.
Amarin Accelerates Timeline For NDA Filing Of AMR101
Positive results from a Phase III trial of Amarin Corporation's triglyceride-lowering drug AMR101 will allow the company to submit its NDA to FDA in 2011, a year ahead of schedule.
Amarin Shuffles Management Again, But Says Omega-3 Trial Results Are Near
On a quarterly earnings call, Amarin's new CEO says two Phase III trials of a drug to lower triglycerides will yield results a few months ahead of schedule.